Mounjaro and dental implant healing

Mounjaro is a dual GLP-1 and GIP receptor agonist. It works similarly to Ozempic (which targets GLP-1 alone) but with an additional GIP effect thought to contribute to its more potent glucose-lowering and weight-loss outcomes. Zepbound is the same medication branded for weight management.

For dental implant healing, tirzepatide itself has not been established as a cause of implant failure. Human evidence on medication-specific effects of GLP-1/GIP therapy on osseointegration remains limited. If you take Mounjaro for type 2 diabetes, its role in supporting glucose control is relevant because the ADA notes that implants are generally reliable in patients with properly controlled diabetes and less predictable when diabetes is poorly controlled — no universal HbA1c cutoff is set; planning is individualized.

Tirzepatide's stronger appetite suppression compared to semaglutide can be a practical hurdle regardless of indication. The first few days after implant surgery, soft and nutritious meals matter. If food is unappealing, smoothies, eggs, yogurt, and protein-rich liquids are easier to tolerate. Some patients time their weekly injection so peak appetite suppression does not coincide with the immediate post-operative window.